公开(公告)号：US12233080B2

公开(公告)日：2025-02-25

申请号：US17037079

申请日：2020-09-29

Applicant: Northwestern University

Inventor： Stephen F. Murphy ,  Praveen Thumbikat ,  Anthony Schaeffer

IPC: A61K39/085 ,  A61K9/00 ,  A61K31/7032 ,  A61K35/00 ,  A61K35/741 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06

Abstract: Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprising S. epidermidis lipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune—(e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).

公开(公告)号：US20210023109A1

公开(公告)日：2021-01-28

申请号：US17037079

申请日：2020-09-29

Applicant: Northwestern University

Inventor： Stephen F. Murphy ,  Praveen Thumbikat ,  Anthony Schaeffer

IPC: A61K31/7032 ,  A61K35/741 ,  A61P29/00 ,  A61P19/02 ,  A61K9/00 ,  A61P37/06

Abstract: Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprising S. epidermidis lipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune- (e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).

公开(公告)号：US20190046588A1

公开(公告)日：2019-02-14

申请号：US16052285

申请日：2018-08-01

Applicant: Northwestern University

Inventor： Jonathan F. Anker ,  Praveen Thumbikat ,  Sarki A. Abdulkadir ,  Anthony J. Schaeffer

IPC: A61K35/74 ,  A61P35/00

Abstract: Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.

公开(公告)号：US11857531B2

公开(公告)日：2024-01-02

申请号：US17395153

申请日：2021-08-05

Applicant: Northwestern University

Inventor： Praveen Thumbikat ,  Anthony J. Schaeffer

IPC: A61K31/352 ,  A61P13/08 ,  A61K31/495

CPC classification number: A61K31/352 ,  A61K31/495 ,  A61P13/08

Abstract: Provided herein are compositions and methods for the treatment of conditions such as benign prostatic hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS), chronic prostatitis (CP) and/or chronic pelvic pain syndrome (CPPS). In particular, provided herein are combination therapies comprising a mast cell inhibitor and a histamine receptor antagonist.

公开(公告)号：US20160058756A1

公开(公告)日：2016-03-03

申请号：US14935976

申请日：2015-11-09

Applicant: Northwestern University

Inventor： Praveen Thumbikat ,  Anthony J. Schaeffer ,  Joseph Done ,  David J. Klumpp ,  Charles Rudick

IPC: A61K31/495 ,  A61K39/395 ,  G01N33/573 ,  A61K31/352 ,  C12Q1/68 ,  C07K16/40 ,  C07K16/24

CPC classification number: A61K31/495 ,  A61K31/341 ,  A61K31/352 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/24 ,  C07K16/40 ,  C07K2317/76 ,  C12Q1/37 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/573 ,  G01N33/6893 ,  G01N2333/96411 ,  G01N2333/96433 ,  G01N2800/10 ,  G01N2800/342 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e g inhibition of MCP-1 and/or MIP-1α) to treat or prevent chronic pelvic pain syndrome.

Abstract translation: 本发明提供用于慢性盆腔疼痛综合征的检测，诊断，治疗和/或预防的组合物和方法。 特别地，本发明提供了慢性盆腔疼痛综合征（例如，肥大细胞标志物（例如类胰蛋白酶））的生物标志物和/或肥大细胞功能的抑制（例如抑制MCP-1和/或MIP-1α）以治疗 或预防慢性盆腔疼痛综合征。

公开(公告)号：US08969340B2

公开(公告)日：2015-03-03

申请号：US13936860

申请日：2013-07-08

Applicant: Northwestern University

Inventor： Anthony J. Schaeffer ,  David Klumpp ,  Praveen Thumbikat

IPC: A61K31/537 ,  A61K31/454 ,  A61K31/495 ,  G01N33/53 ,  C12Q1/68 ,  G01N33/68 ,  A61K31/351 ,  A61K31/40

CPC classification number: A61K31/537 ,  A61K31/351 ,  A61K31/40 ,  A61K31/454 ,  A61K31/495 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/52 ,  G01N2800/2842 ,  G01N2800/36

Abstract: The present invention provides methods and compositions for treating chronic pelvic pain syndrome. In particular, the present invention provides methods and compositions for treating chronic pelvic pain syndrome with an agent that targets MCP-1, MIP-1α, or the CCR-2 receptor.

Abstract translation: 本发明提供治疗慢性盆腔疼痛综合征的方法和组合物。 特别地，本发明提供了用靶向MCP-1，MIP-1α或CCR-2受体的药物治疗慢性盆腔疼痛综合征的方法和组合物。

公开(公告)号：US09181577B2

公开(公告)日：2015-11-10

申请号：US14084337

申请日：2013-11-19

Applicant: Northwestern University

Inventor： Praveen Thumbikat ,  Anthony J. Schaeffer ,  Joseph Done ,  David J. Klumpp ,  Charles Rudick

IPC: A61K39/395 ,  C07K16/24 ,  C12P21/08 ,  A01N43/16 ,  C12Q1/37 ,  A61K45/06 ,  C12Q1/68 ,  G01N33/68 ,  A61K31/341 ,  A61K31/352 ,  A61K31/495 ,  A61K39/00

CPC classification number: A61K31/495 ,  A61K31/341 ,  A61K31/352 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/24 ,  C07K16/40 ,  C07K2317/76 ,  C12Q1/37 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/573 ,  G01N33/6893 ,  G01N2333/96411 ,  G01N2333/96433 ,  G01N2800/10 ,  G01N2800/342 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1α) to treat or prevent chronic pelvic pain syndrome.

Abstract translation: 本发明提供用于慢性盆腔疼痛综合征的检测，诊断，治疗和/或预防的组合物和方法。 特别地，本发明提供了慢性盆腔疼痛综合征（例如，肥大细胞标志物（例如类胰蛋白酶））的生物标志物和/或肥大细胞功能的抑制（例如抑制MCP-1和/或MIP-1α）以治疗 或预防慢性盆腔疼痛综合征。

公开(公告)号：US20240252552A1

公开(公告)日：2024-08-01

申请号：US18418897

申请日：2024-01-22

Applicant: Northwestern University

Inventor： Praveen Thumbikat

IPC: A61K35/74 ,  A61K31/7032 ,  A61P25/04

CPC classification number: A61K35/74 ,  A61K31/7032 ,  A61P25/04

Abstract: Disclosed herein are compositions comprising lipoteichoic acid (LTA) and the use thereof for modulating neuronal activity. The disclosed LTA compositions may be prepared using LTA that is derived from the Gram positive bacteria Staphylococcus epidermidis. The disclosed LTA compositions may be administered to treat pain, including but not limited to chronic pelvic pain syndrome (CPPS), neurogenic pain, or neurogenic inflammation via PD-1 inhibitory signaling in neurons. The disclosed LTA compositions may be administered in order to modulate the expression of endogenous opioids.

公开(公告)号：US11865144B2

公开(公告)日：2024-01-09

申请号：US16052285

申请日：2018-08-01

Applicant: Northwestern University

Inventor： Jonathan F. Anker ,  Praveen Thumbikat ,  Sarki A. Abdulkadir ,  Anthony J. Schaeffer

IPC: A61K35/74 ,  A61P35/00 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28 ,  A61K39/108 ,  A61K39/395

CPC classification number: A61K35/74 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/0258 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/523 ,  A61K2039/585 ,  A61K2039/884 ,  C12N2740/16043 ,  A61K39/3955 ,  A61K2300/00 ,  A61K39/0258 ,  A61K2300/00

Abstract: Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.

公开(公告)号：US20180280419A1

公开(公告)日：2018-10-04

申请号：US15923679

申请日：2018-03-16

Applicant: Northwestern University

Inventor： Stephen F. Murphy ,  Praveen Thumbikat ,  Anthony Schaeffer

IPC: A61K31/7032 ,  A61K35/741 ,  A61P29/00 ,  A61P37/06 ,  A61P19/02 ,  A61K9/00

CPC classification number: A61K31/7032 ,  A61K9/0031 ,  A61K9/0053 ,  A61K35/741 ,  A61K2035/115 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06

Abstract: Provided herein are compositions comprising lipotechoic acid (LTA) and methods of use thereof for immune modulation. In particular, compositions comprising S. epidermidis lipotechoic Acid (SELTA) are provided, as well as method of use thereof for the treatment of immune- (e.g., autoimmune) and inflammation-related conditions and diseases (e.g., chronic pelvic pain syndrome (CPPS), arthritis, etc.).